MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 887-893

  Hoshi, Hirotaka ^a,b   Sawada, Tetsuji ^b   Uchida, Motoyuki ^a   Iijima, Hiroko ^a   Kimura, Kenjiro ^b   Hirakawa, Kosei ^b   Wanibuchi, Hideki ^b  

^a KUREHA CORPORATION   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; MUC5AC; Mucin; Pancreatic cancer; Short interfering RNA; TNF related apoptosis inducing ligand

Indexed keywords

CASPASE 3; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GR 1; MUCIN 5AC; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GROWTH INHIBITION; HOST CELL; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOCOMPETENT CELL; MOUSE; NEUTROPHIL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; T CELL DEPLETION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MUCIN 5AC; NEOPLASM TRANSPLANTATION; NEUTROPHILS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873623576     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1760     Document Type: Article

References (29)

1. Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, Kong D, Wang S, Sarkar FH and Mohammad RM: TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 123: 958-966, 2008. (Pubitemid 352032427)
2. Sheehan JK, Brazeau C, Kutay S, Pigeon H, Kirkham S, Howard M and Thornton DJ: Physical characterization of the MUC5AC mucin: a highly oligomeric glycoprotein whether isolated from cell culture or in vivo from respiratory mucous secretions. Biochem J 347: 37-44, 2000. (Pubitemid 30199038)
3. Hollingsworth MA and Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60, 2004. (Pubitemid 38082153)
4. Ho JJL, Crawley S, Pan PL, Farrelly ER and Kim YS: Secretion of MUC5AC mucin from pancreatic cancer cells in response to forskolin and VIP. Biochem Biophys Res Commun 294: 680-686, 2002. (Pubitemid 34694065)
5. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L and Cassatella MA: IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103: 3837-3844, 2004. (Pubitemid 38596303)
6. Stockmeyer B, Beyer T, Neuhuber W, Repp R, Kalden JR, Valerius T and Herrmann M: Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 171: 5124-5129, 2003. (Pubitemid 37432795)
7. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, Le TT, Hoang-Le D and Ogbourne SM: Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 177: 8123-8132, 2006. (Pubitemid 44846331)
8. Koga Y, Matsuzaki A, Suminoe A, Hattori H and Hara T: Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res 64: 1037-1043, 2004. (Pubitemid 38176907)
9. Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, Leidal K, Nauseef WM and Griffith TS: Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 106: 3474-3482, 2005. (Pubitemid 41609183)
10. de Vries EG, Gietema JA and de Jong S: Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res 12: 2390-2393, 2006.
11. Voortman J, Resende TP, Abou EI Hassan MA, Giaccone G and Kruyt FA: TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6: 2103-2112, 2007. (Pubitemid 47052501)
12. Hoshi H, Sawada T, Uchida M, Saito H, Iijima H, Toda Agetsuma M, Wada T, Yamazoe S, Tanaka H, Kimura K, Kakehashi A, Wei M, Hirakawa K and Wanibuchi H: Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int J Oncol 38: 619-627, 2011.
13. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E and Czuczman MS: Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 9: 5866-5873, 2003. (Pubitemid 38018069)
14. Singh PK and Hollingsworth MA: Cell surface-associated mucins in signal transduction. Trends Cell Biol 16: 467-476, 2006. (Pubitemid 44293402)
15. Lane D, Côté M, Grondin R, Couture MC and Piché A: Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther 5: 509-521, 2006.
16. Lane D, Robert V, Grondin R, Rancourt C and Piché A: Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 121: 1227-1237, 2007. (Pubitemid 47293789)
17. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A and Musiani P: The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339-345, 2001. (Pubitemid 32060315)
18. Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, Pitossi FJ, Chuluyan HE and Podhajcer OL: Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 65: 5123-5132, 2005. (Pubitemid 40827321)
19. Chen YL, Chen SH, Wang JY and Yang BC: Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 171: 1183-1191, 2003.
20. Sanford MA, Yan Y, Canfield SE, Hassan W, Selleck WA, Atkinson G, Chen SH and Hall SJ: Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum Gene Ther 12: 1485-1498, 2001. (Pubitemid 34248285)
21. Niitsu N, Khori M, Hayama M, Kajiwara K, Higashihara M and Tamaru J: Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels. Clin Cancer Res 11: 697-702, 2005. (Pubitemid 40116897)
22. Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG and van Egmond M: Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 174: 5472-5480, 2005. (Pubitemid 40593187)
23. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and Goodwin RG: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
24. Schimmer AD: Inhibition of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64: 7183-7190, 2004. (Pubitemid 39372048)
25. Wei Y, Fan T and Yu M: Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai) 40: 278-288, 2009. (Pubitemid 351572108)
26. Komatsu M, Jepson S, Arango ME, Carraway CAC and Carraway KL: Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 20: 461-470, 2001. (Pubitemid 32158226)
27. Workman HC, Sweeney C, Carraway KL III: The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 69: 2845-2852, 2009.
28. Baratelli F, Krysan K, Heuzé-Vourc'h N, Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M and Dubinett SM: PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol 78: 555-564, 2005. (Pubitemid 41061327)
29. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, Iuliano F and Acquaviva AM: PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 293: G673-G681, 2007. (Pubitemid 47605921)